Is serological follow-up useful for patients with cutaneous lyme borreliosis?

Current Problems in Dermatology

Volumn 37, Issue , 2009, Pages 178-182

  Mullegger R R ^a   Glatz, M ^b  

^a State Hospital Wiener Neustadt   (Austria)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CEFUROXIME; DOXYCYCLINE; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ACRODERMATITIS CHRONICA ATROPHICANS; ANTIBIOTIC THERAPY; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIMICROBIAL THERAPY; BACTERIUM CULTURE; BORRELIA BURGDORFERI; BORRELIA INFECTION; BORRELIA LYMPHOCYTOMA; BORRELIAL LYMPHOCYTOMA; CLINICAL ASSESSMENT; CLINICAL EXAMINATION; DIAGNOSTIC VALUE; DISEASE COURSE; DRUG EFFICACY; DRUG TREATMENT FAILURE; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; FOLLOW UP; HUMAN; LABORATORY TEST; LYME DISEASE; OUTCOME ASSESSMENT; PARAMETER; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SEROCONVERSION; SEROLOGY; SKIN BIOPSY; SKIN MANIFESTATION; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ARTICLE; BACTERIAL SKIN DISEASE; BLOOD;

HUMANS; LYME DISEASE; SEROLOGIC TESTS; SKIN DISEASES, BACTERIAL;

EID: 67649560054     PISSN: 14215721     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000213075     Document Type: Review

References (19)

1. Müllegger RR: Dermatological manifestations of Lyme borreliosis. Eur J Dermatol 2004;14:296-309.
2. Dumler JS: Molecular diagnosis of Lyme disease: review and meta-analysis. Mol Diagn 2001;6:1-11.
3. Lebech AM, Hansen K, Bandrup F, Clemmensen O, Halkier-Sorensen L: Diagnostic value of PCR for detection of Borrelia burgdorferi DNA in clinical specimens from patients with erythema migrans and Lyme neuroborreliosis. Mol Diagn 2000;5:139-150.
4. Hunfeld KP, Ruzic-Sabljic E, Norris DE, Kraiczy P, Strle F: In vitro susceptibility testing of Borrelia burgdorferi sensu lato isolates cultured from patients with erythema migrans before and after antimicrobial chemotherapy. Antimicrob Agents Chemother 2005;49:1294-1301.
5. Müllegger RR, Zöchling N, Schlüpen EM, Soyer HP, Hödl S, Kerl H, Volkenandt M: Polymerase chain reaction control of antibiotic treatment in dermatoborreliosis. Infection 1996;24:76-79.
6. Glatz M, Golestani M, Kerl H, Müllegger RR: Clinical relevance of different IgG and IgM serum antibody responses to Borrelia burgdorferi after antibiotic therapy for erythema migrans: long-term follow-up study of 113 patients. Arch Dermatol 2006;142:862-868.
7. Feder HM Jr, Gerber MA, Luger SW, Ryan RW: Persistence of serum antibodies to Borrelia burgdorferi in patients treated for Lyme disease. Clin Infect Dis 1992;15:788-793.
8. Hulshof MM, Vandenbroucke JP, Nohlmans LM, Spanjaard L, Bavnick JN, Dijkmans BA: Long-term prognosis in patients treated for erythema chronicum migrans and acrodermatitis chronica atrophicans. Arch Dermatol 1997;133:33-37.
9. Lomholt H, Lebech AM, Hansen K, Bandrup F, Halkier-Sorensen L: Long-term serological followup of patients treated for chronic cutaneous borreliosis or cu lture-positive er y thema migrans. Acta Derm Venereol 2000;80:362-366.
10. Asbrink E, Hovmark A, Hederstedt B: Serologic studies of erythema chronicum migrans Afzelius and acrodermatitis chronica atrophicans with indirect immunofluorescence and enzyme-linked immunosorbent assays. Acta Derm Venereol 1985;65:509-514.
11. Hammers-Berggren S, Lebech AM, Karlsson M, Svenungsson B, Hansen K, Stiernstedt G: Serological follow-up after treatment of patients with erythema migrans and neuroborreliosis. J Clin Microbiol 1994;32:1519-1525.
12. Kalish R A, McHugh G, Granquist J, Shea B, Ruthazer R, Steere AC: Persistence of immunoglobulin M or immunoglobulin G antibody responses to Borrelia burgdorferi 10-20 years after active Lyme disease. Clin Infect Dis 2001;33:780-785.
13. Bernasconi NL, Traggiai E, Lanzavecchia A: Maintenance of serological memory by polyclonal activation of human memory B-cells. Science 2002;298:2199-2202.
14. Glatz M, Fingerle V, Wilske B, Ambros-Rudolph C, Kerl H, Müllegger RR: Immunoblot analysis of the seroreactivity to recombinant Borrelia burgdorferi sensu lato antigens, including VlsE, in the longterm course of treated patients with erythema migrans. Dermatology 2008;216:93-103.
15. Marangoni A, Sambri V, Accardo S, Cavrini F, Mondardini V, Moroni A, Storni E, Cevenini R: A decrease in the immunoglobulin G antibody response against the VlsE protein of Borrelia burgdorferi sensu lato correlates with the resolution of clinical signs in antibiotic-treated patients with early Lyme disease. Clin Vaccine Immunol 2006;13:525-529.
16. Philipp MT, Wormser GP, Marques AR, Bittker S, Martin DS, Nowakowski J, Dally LG: A decline in C6 antibody titer occurs in successfully treated patients with culture-confirmed early localized or early disseminated Lyme borreliosis. Clin Diagn Lab Immunol 2005;12:1069-1074.
17. Peltomaa M, McHugh G, Steere AC: Persistence of the antibody response to the sixth invariant region (IR6) peptide of Borrelia burgdorferi after successful antibiotic treatment of Lyme disease. J Infect Dis 2003;187:1178-1186.
18. Maraspin V, Cimperman J, Lotric-Furlan S, Ruzic-Sabljic E, Jurca T, Picken R, Strle F: Solitary borrelial lymphocytoma in adult patients. Wien Klin Wochenschr 2002;114:515-523.
19. Olsson I, Asbrink E, von-Stedingk M, von-Stedingk LV: Changes in Borrelia burgdorferi-specific serum IgG antibody levels in patients treated for acrodermatitis chronica atrophicans. Acta Derm Venereol (Stockh) 1994;74:424-428.